Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell Lymphoma

NCT05976763 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT05976763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05976763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell Lymphoma
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
October 20, 2023
Completion date
August 31, 2038
Enrollment
421 (estimated)
Sites
238

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma